JP2764306B2 - Electrophoresis support - Google Patents
Electrophoresis supportInfo
- Publication number
- JP2764306B2 JP2764306B2 JP1126287A JP12628789A JP2764306B2 JP 2764306 B2 JP2764306 B2 JP 2764306B2 JP 1126287 A JP1126287 A JP 1126287A JP 12628789 A JP12628789 A JP 12628789A JP 2764306 B2 JP2764306 B2 JP 2764306B2
- Authority
- JP
- Japan
- Prior art keywords
- electrophoresis
- polymer
- ppm
- support
- film
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000001962 electrophoresis Methods 0.000 title claims description 35
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 17
- 229930195729 fatty acid Natural products 0.000 claims description 17
- 239000000194 fatty acid Substances 0.000 claims description 17
- 150000004665 fatty acids Chemical class 0.000 claims description 17
- 229920000642 polymer Polymers 0.000 claims description 16
- 125000004432 carbon atom Chemical group C* 0.000 claims description 6
- 239000000654 additive Substances 0.000 claims description 4
- 230000000996 additive effect Effects 0.000 claims description 4
- 229920002678 cellulose Polymers 0.000 claims description 3
- 229920000915 polyvinyl chloride Polymers 0.000 claims description 2
- 239000004800 polyvinyl chloride Substances 0.000 claims description 2
- 239000004952 Polyamide Substances 0.000 claims 1
- 229920002647 polyamide Polymers 0.000 claims 1
- 239000002904 solvent Substances 0.000 description 20
- 239000000243 solution Substances 0.000 description 13
- 102000006395 Globulins Human genes 0.000 description 12
- 108010044091 Globulins Proteins 0.000 description 12
- 108010007622 LDL Lipoproteins Proteins 0.000 description 12
- 102000007330 LDL Lipoproteins Human genes 0.000 description 12
- 239000011148 porous material Substances 0.000 description 11
- 238000000034 method Methods 0.000 description 10
- 108010017384 Blood Proteins Proteins 0.000 description 9
- 102000004506 Blood Proteins Human genes 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 230000003287 optical effect Effects 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 238000005194 fractionation Methods 0.000 description 8
- 229920006254 polymer film Polymers 0.000 description 8
- 239000002861 polymer material Substances 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- UYXTWWCETRIEDR-UHFFFAOYSA-N Tributyrin Chemical compound CCCC(=O)OCC(OC(=O)CCC)COC(=O)CCC UYXTWWCETRIEDR-UHFFFAOYSA-N 0.000 description 6
- 229920002301 cellulose acetate Polymers 0.000 description 6
- 238000013508 migration Methods 0.000 description 6
- 230000005012 migration Effects 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000004014 plasticizer Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 239000000080 wetting agent Substances 0.000 description 5
- FTOAOBMCPZCFFF-UHFFFAOYSA-N 5,5-diethylbarbituric acid Chemical compound CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 4
- 102000006734 Beta-Globulins Human genes 0.000 description 4
- 108010087504 Beta-Globulins Proteins 0.000 description 4
- 229920001747 Cellulose diacetate Polymers 0.000 description 4
- 229920002284 Cellulose triacetate Polymers 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- NNLVGZFZQQXQNW-ADJNRHBOSA-N [(2r,3r,4s,5r,6s)-4,5-diacetyloxy-3-[(2s,3r,4s,5r,6r)-3,4,5-triacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6s)-4,5,6-triacetyloxy-2-(acetyloxymethyl)oxan-3-yl]oxyoxan-2-yl]methyl acetate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](OC(C)=O)[C@H]1OC(C)=O)O[C@H]1[C@@H]([C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)O1)OC(C)=O)COC(=O)C)[C@@H]1[C@@H](COC(C)=O)O[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O NNLVGZFZQQXQNW-ADJNRHBOSA-N 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 238000004043 dyeing Methods 0.000 description 4
- XMHIUKTWLZUKEX-UHFFFAOYSA-N hexacosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCC(O)=O XMHIUKTWLZUKEX-UHFFFAOYSA-N 0.000 description 4
- VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 description 4
- 239000012982 microporous membrane Substances 0.000 description 4
- 229920006122 polyamide resin Polymers 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 239000000020 Nitrocellulose Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000012046 mixed solvent Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 229920001220 nitrocellulos Polymers 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 102100027211 Albumin Human genes 0.000 description 2
- 238000008214 LDL Cholesterol Methods 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 2
- ZFOZVQLOBQUTQQ-UHFFFAOYSA-N Tributyl citrate Chemical compound CCCCOC(=O)CC(O)(C(=O)OCCCC)CC(=O)OCCCC ZFOZVQLOBQUTQQ-UHFFFAOYSA-N 0.000 description 2
- 108010069201 VLDL Cholesterol Proteins 0.000 description 2
- FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 229960002319 barbital Drugs 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- WERYXYBDKMZEQL-UHFFFAOYSA-N butane-1,4-diol Chemical compound OCCCCO WERYXYBDKMZEQL-UHFFFAOYSA-N 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- CKDDRHZIAZRDBW-UHFFFAOYSA-N henicosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCC(O)=O CKDDRHZIAZRDBW-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 2
- 229910052753 mercury Inorganic materials 0.000 description 2
- TZIHFWKZFHZASV-UHFFFAOYSA-N methyl formate Chemical compound COC=O TZIHFWKZFHZASV-UHFFFAOYSA-N 0.000 description 2
- MWMPEAHGUXCSMY-UHFFFAOYSA-N pentacosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCC(O)=O MWMPEAHGUXCSMY-UHFFFAOYSA-N 0.000 description 2
- 239000012192 staining solution Substances 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- XEZVDURJDFGERA-UHFFFAOYSA-N tricosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCCC(O)=O XEZVDURJDFGERA-UHFFFAOYSA-N 0.000 description 2
- HDDLVZWGOPWKFW-UHFFFAOYSA-N trimethyl 2-hydroxypropane-1,2,3-tricarboxylate Chemical compound COC(=O)CC(O)(C(=O)OC)CC(=O)OC HDDLVZWGOPWKFW-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- AXDJCCTWPBKUKL-UHFFFAOYSA-N 4-[(4-aminophenyl)-(4-imino-3-methylcyclohexa-2,5-dien-1-ylidene)methyl]aniline;hydron;chloride Chemical compound Cl.C1=CC(=N)C(C)=CC1=C(C=1C=CC(N)=CC=1)C1=CC=C(N)C=C1 AXDJCCTWPBKUKL-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- DQEFEBPAPFSJLV-UHFFFAOYSA-N Cellulose propionate Chemical compound CCC(=O)OCC1OC(OC(=O)CC)C(OC(=O)CC)C(OC(=O)CC)C1OC1C(OC(=O)CC)C(OC(=O)CC)C(OC(=O)CC)C(COC(=O)CC)O1 DQEFEBPAPFSJLV-UHFFFAOYSA-N 0.000 description 1
- YUXIBTJKHLUKBD-UHFFFAOYSA-N Dibutyl succinate Chemical compound CCCCOC(=O)CCC(=O)OCCCC YUXIBTJKHLUKBD-UHFFFAOYSA-N 0.000 description 1
- DKMROQRQHGEIOW-UHFFFAOYSA-N Diethyl succinate Chemical compound CCOC(=O)CCC(=O)OCC DKMROQRQHGEIOW-UHFFFAOYSA-N 0.000 description 1
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 1
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- KMNTUASVUKNVJS-UHFFFAOYSA-N Ponceau S (acid form) Chemical compound OC1=C(S(O)(=O)=O)C=C2C=C(S(O)(=O)=O)C=CC2=C1N=NC(C(=C1)S(O)(=O)=O)=CC=C1N=NC1=CC=C(S(O)(=O)=O)C=C1 KMNTUASVUKNVJS-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 229920006217 cellulose acetate butyrate Polymers 0.000 description 1
- 229920006218 cellulose propionate Polymers 0.000 description 1
- 238000003889 chemical engineering Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229960002097 dibutylsuccinate Drugs 0.000 description 1
- WYACBZDAHNBPPB-UHFFFAOYSA-N diethyl oxalate Chemical compound CCOC(=O)C(=O)OCC WYACBZDAHNBPPB-UHFFFAOYSA-N 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- HZHMMLIMOUNKCK-UHFFFAOYSA-N dipropyl oxalate Chemical compound CCCOC(=O)C(=O)OCCC HZHMMLIMOUNKCK-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- AGDANEVFLMAYGL-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCCCCCC(O)=O AGDANEVFLMAYGL-UHFFFAOYSA-N 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- -1 hydroxypropyl Chemical group 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000000951 immunodiffusion Effects 0.000 description 1
- 238000000760 immunoelectrophoresis Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- QVJXYCFQBBHRJN-UHFFFAOYSA-N nonadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCCC(O)=O QVJXYCFQBBHRJN-UHFFFAOYSA-N 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000003909 pattern recognition Methods 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229920005597 polymer membrane Polymers 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 1
- RGHFKWPGWBFQLN-UHFFFAOYSA-M sodium;5,5-diethylpyrimidin-3-ide-2,4,6-trione Chemical compound [Na+].CCC1(CC)C([O-])=NC(=O)NC1=O RGHFKWPGWBFQLN-UHFFFAOYSA-M 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- CBYCSRICVDBHMZ-UHFFFAOYSA-N tetracosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCCCCCCCC(O)=O CBYCSRICVDBHMZ-UHFFFAOYSA-N 0.000 description 1
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 239000001069 triethyl citrate Substances 0.000 description 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
- 235000013769 triethyl citrate Nutrition 0.000 description 1
- XZZNDPSIHUTMOC-UHFFFAOYSA-N triphenyl phosphate Chemical compound C=1C=CC=CC=1OP(OC=1C=CC=CC=1)(=O)OC1=CC=CC=C1 XZZNDPSIHUTMOC-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Separation Using Semi-Permeable Membranes (AREA)
- Manufacture Of Porous Articles, And Recovery And Treatment Of Waste Products (AREA)
Description
【発明の詳細な説明】 [産業上の利用分野] 本発明は、微多孔性高分子皮膜からなる電気泳動用支
持体に関するものであり、特に血清蛋白の分画用として
好適な支持体に関するものである。Description: TECHNICAL FIELD The present invention relates to a support for electrophoresis comprising a microporous polymer film, and more particularly to a support suitable for fractionating serum proteins. It is.
[従来の技術] 電気泳動法は荷電物質の分離、精製に用いられてお
り、特に蛋白質の分離、分画に有用な方法である。電気
泳動法には一般の電気泳動法の他に不連続緩衝液系を用
い、分離を行うディスク(Disc)電気泳動法、免疫拡散
反応によって分離、検出を行う免疫電気泳動法、pH勾配
を電極間に形成させ、そのpH勾配の中で分離、分画を行
う等電点分画法等の方法がある。[Prior Art] Electrophoresis is used for separating and purifying charged substances, and is particularly useful for separating and fractionating proteins. For electrophoresis, in addition to general electrophoresis, a discontinuous buffer system is used, disc electrophoresis for separation, immunoelectrophoresis for separation and detection by immunodiffusion, and pH gradient There is a method such as an isoelectric point fractionation method in which the particles are formed in the middle and separated and fractionated in the pH gradient.
血清蛋白の分画は、臨床検査の分野で行なわれてお
り、この目的のために、セルロースアセテートなどの高
分子を主成分とした微多孔性皮膜からなる電気泳動用支
持体が多数用いられている。Fractionation of serum proteins is performed in the field of clinical testing, and for this purpose, a large number of electrophoresis supports composed of a microporous film mainly composed of a polymer such as cellulose acetate are used. I have.
高分子微多孔性支持体としてセルロースアセテート微
多孔性膜を用いて血清蛋白を電気泳動により分画する方
法として、濃度0.03〜0.08モル/L、pH8.6の緩衝液に微
多孔性膜を浸漬した後、血清を微多孔性膜表面に塗布し
直流電流を印加し蛋白質を電気泳動させて分画後、蛋白
質を染色する方法がある。染色用染料として、ポンソー
−3R、ポンソー−S、ニグロシン、アミドブラック、ク
マシーブリリアントブルー等の染料が用いられる。この
ようにして得られた分画染料像は通常5つの分画に分か
れており、陽極側から順にアルブミン分画、α1グロブ
リン分画、α2グロブリン分画、βグロブリン分画、γ
グロブリン分画と命名されている。As a method for fractionating serum proteins by electrophoresis using a cellulose acetate microporous membrane as a polymer microporous support, immersing the microporous membrane in a buffer solution with a concentration of 0.03 to 0.08 mol / L and pH 8.6 Then, serum is applied to the surface of the microporous membrane, a direct current is applied, the protein is electrophoresed, fractionated, and then the protein is stained. As the dye for dyeing, dyes such as Ponceau-3R, Ponceau-S, nigrosine, amide black, Coomassie brilliant blue and the like are used. Thus fractionation dye images obtained are usually divided into five fractions, albumin fraction in order from the anode side, alpha 1 globulin fraction, alpha 2 globulin, beta globulin fraction, gamma
It is named the globulin fraction.
血清蛋白は、電気泳動分析の上では大きく5つの分画
に分けられるが、5つの分画の各々が、同一の化学成分
に属するものではなく、たまたま電気による易動度とい
る点で、5つに分けられたのであって、化学構造的には
全く異なる種別に属する成分が1つの分画に共存するに
すぎない。例えば、βグロブリン分画にはグロブリン成
分のほか、LDLコレストロールと蛋白の複合体が共存す
る。またα2グロブリン分画には、グロブリン成分のほ
かに、VLDLコレステロールと蛋白の複合体が含まれる。Serum proteins are roughly divided into five fractions on electrophoretic analysis. However, each of the five fractions does not belong to the same chemical component and happens to have mobility due to electricity. In this case, components belonging to completely different types in chemical structure only coexist in one fraction. For example, in the β globulin fraction, in addition to the globulin component, a complex of LDL cholesterol and a protein coexists. Also the alpha 2 globulin fraction, in addition to the globulin components include complexes of VLDL cholesterol and proteins.
電気泳動による血清蛋白の分画は血清中の蛋白質を、
化学構造的に、単純明解に5系統に分類するものではな
いが、臨床検査の一次スクリーニングとして、先づ5つ
の分画にわけ、それぞれの分画値が正常値と大きく異っ
た値になっていないか確認するために行なわれるもので
ある。一次スクリーニングとして先ず上記の5分画の検
査を行った上で、問題のある結果が得られたら、更に精
密な蛋白検査が実施されるのが常である。Fractionation of serum proteins by electrophoresis
In terms of chemical structure, it is not a simple and straightforward classification into five strains, but as a primary screening of clinical tests, it is first divided into five fractions, and each fraction value is significantly different from the normal value. This is done to confirm that they are not present. As a primary screening, the above-mentioned five fractions are first tested, and if a problematic result is obtained, a more precise protein test is usually performed.
[従来の技術の問題点] 近年、自動分析機器により、検査結果をコンピュータ
ーからデジタル又はアナログアウトプットして読み取る
方法が普及している。自動読み取り法は病態を更に正確
によみとれるという利点がある反面、通常血清蛋白を5
分画に分類している中で、わずかの変動により余分なピ
ークが発生したり、ピークの間隔が不揃いになると、自
動処理によるパターン認識の面で混乱が生じ、誤った読
み取りをすることがある。従って、多少の変動やピーク
間隔の不揃いが生じても一次スクリーニングを目的とし
た血清分画では、殆ど全ての血清に関して識別しやすい
5分画になるような分画性を持つ電気泳動用支持体の開
発が望まれている。[Problems of the Related Art] In recent years, a method of reading out a test result by digital or analog output from a computer by an automatic analyzer has become widespread. While the automatic reading method has the advantage that the disease state can be detected more accurately, the serum protein is usually used for 5 times.
During classification, if small fluctuations cause extra peaks or irregular peak intervals, confusing pattern recognition by automatic processing may result in erroneous reading. . Therefore, even if a slight variation or irregularity of peak intervals occurs, in the serum fractionation for the purpose of the primary screening, the support for electrophoresis has a fractionation property such that almost all sera can be distinguished into 5 fractions. The development of is desired.
VLDLコレステロールやLDLコレステロールと蛋白質と
の複合体の場合(各々プレβリポ蛋白、βリポ蛋白と呼
ばれる)、含有量の多少により、分画される位置が異っ
てくる。例えば、α2グロブリン分画(第3分画)とβ
グロブリン分画(第4分画)の間にβリポ蛋白の分画
(第6分画)が生じ、さらにこのβリポ蛋白の分画は、
βリポ蛋白の含有量に応じてα2グロブリン分画(第3
分画)とβグロブリン分画(第4分画)の間で位置が変
動する(含有量が少ないとα2グロブリン分画に含まれ
るが、含有量が増大するとα2グロブリン分画とβグロ
ブリン分画の間に独立の分画となる)。このように第6
番目の分画が現われると、5分画を原則とした検査結果
を判断するのに障害になることが多い。In the case of VLDL cholesterol or a complex of LDL cholesterol and a protein (referred to as pre-β lipoprotein and β-lipoprotein, respectively), the fractionated position differs depending on the content. For example, alpha 2 globulin fraction (third fraction) beta
A β-lipoprotein fraction (sixth fraction) is generated between the globulin fraction (fourth fraction), and this β-lipoprotein fraction is
Depending on the content of β lipoprotein alpha 2 globulin fraction (Third
Fraction) and β-globulin fraction (fourth fraction) is located between are included in the alpha 2 globulin fraction is (the content is less variation, if the content is increased alpha 2 globulin fraction and β-globin Independent fractionation between fractions). Thus the sixth
When the second fraction appears, it often becomes an obstacle to judge the test result based on five fractions.
この障害は、例えば特開昭63−262549に記載の孔径分
布範囲0.1μm〜2.0μmの微多孔性高分子皮膜からなる
電気泳動用支持体、特開昭63−262550に記載の特定の湿
潤剤又は可塑剤を高分子の重量に対して20%以下の割合
で添加した微多孔性高分子皮膜からなる電気泳動用支持
体によって改善されたが、まだ解決されたとは言い難い
状況であった。さらに、これらの電気泳動用支持体によ
ってもなお分離された蛋白のピーク間隔の不揃いは充分
に解消されないままであった。This obstacle is, for example, a support for electrophoresis comprising a microporous polymer film having a pore size distribution range of 0.1 μm to 2.0 μm described in JP-A-63-262549, a specific wetting agent described in JP-A-63-262550. Alternatively, it was improved by an electrophoresis support comprising a microporous polymer film to which a plasticizer was added at a ratio of 20% or less based on the weight of the polymer, but the situation was not yet solved. Furthermore, even with these electrophoretic supports, the irregularity of the peak intervals of the proteins separated still remained unresolved.
[発明が解決しようとする問題点] 本発明の目的は諸種の血清に広く適用できる電気泳動
用支持体を提供することにあり、特にβリポ蛋白を多く
含む血清についても、βリポ蛋白による6番目の分画に
よる余分なピークが発生したり、βリポ蛋白の含有量の
違いによるβリポ蛋白のピークの位置の移動に起因する
分離性不良が生じない電気泳動用支持体を提供すること
にある。[Problems to be Solved by the Invention] An object of the present invention is to provide a support for electrophoresis which can be widely applied to various kinds of serums. To provide a support for electrophoresis in which an extra peak due to the second fractionation does not occur, and a poor separation property does not occur due to a shift in the position of the β lipoprotein peak due to a difference in β lipoprotein content. is there.
本発明の他の目的はα2グロブリン分画の泳動像濃度
とβグロブリン分画の泳動像濃度の間の泳動像濃度が著
しく低下したコントラストの高い読取りやすい泳動像を
与える電気泳動用支持体を提供することにある。Other objects are alpha 2 globulin fraction of electrophoresis image density and β-globulin fraction of the electrophoresis image density electrophoresis support the electrophoresis image density gives a high read easily electrophoresis image of significantly reduced contrast between the present invention To provide.
本発明の他の目的は取り扱い操作の容易な実質的に乾
燥した電気泳動用支持体を提供することにある。Another object of the present invention is to provide a substantially dry support for electrophoresis which is easy to handle.
本発明の他の目的は特開昭63−262549及び特開昭63−
262550に記載の微多孔性高分子皮膜からなる電気泳動用
支持体を改良したものを提供することにある。Other objects of the present invention are described in JP-A-63-262549 and JP-A-63-262549.
An object of the present invention is to provide an improved electrophoresis support comprising the microporous polymer film described in 262550.
[問題点を解決するための手段] 本発明は、 添加剤として炭素原子数10から27の範囲の高級脂肪酸
の少なくとも1種を高分子に対して重量比で10ppmから3
000ppmの範囲又は10ppmから溶解度の範囲内で含有する
ことを特徴とする高分子微多孔性皮膜からなる電気泳動
用支持体である。[Means for Solving the Problems] The present invention provides an additive comprising at least one kind of higher fatty acid having 10 to 27 carbon atoms in a weight ratio to a polymer of 10 ppm to 3 ppm.
A support for electrophoresis comprising a polymer microporous film, which is contained in the range of 000 ppm or in the range of 10 ppm to solubility.
[発明の構成の詳細な説明] 本発明の高分子微多孔性皮膜からなる電気泳動用支持
体は、特公昭55−31418、特開昭63−262549及び特開昭6
3−262550に記載の高分子微多孔性皮膜からなる電気泳
動用支持体を改良したもので、その特徴は、添加剤とし
てカルボキシル基の炭素原子を含めて炭素原子数10から
27の範囲の高級脂肪酸の1種又は複数種を高分子に対し
て重量比で約10ppmから約3000ppmの範囲(溶解度が3000
ppm以下の脂肪酸の場合には約10ppmから溶解度の範囲
内)で含有する点にある。[Detailed Description of the Structure of the Invention] The electrophoresis support comprising the polymer microporous film of the present invention is disclosed in JP-B-55-31418, JP-A-63-262549 and JP-A-63-262549.
An improved electrophoretic support comprising a microporous polymer film described in 3-262550, characterized by a carbon number of 10 including carbon atoms of a carboxyl group as an additive.
One or more of the higher fatty acids in the range of 27 to about 10 ppm to about 3000 ppm by weight of the polymer (with a solubility of 3000
In the case of fatty acids of less than ppm, it is contained in the range of about 10 ppm to the solubility).
本発明の高分子微多孔性皮膜からなる電気泳動用支持
体は実質的に乾燥した皮膜で、厚さ約50μmから約300
μm、好ましくは約100μmから約200μm、最も好まし
くは約100μmから約150μmの範囲である。微孔の孔径
範囲は約0.1μmから約10μm、好ましくは約0.1μmか
ら約2.0μmの範囲である。微孔のしめる空隙率は約50
%から約90%、好ましくは約60%から約85%の範囲であ
る。The support for electrophoresis comprising the polymer microporous film of the present invention is a substantially dry film, having a thickness of about 50 μm to about 300 μm.
μm, preferably from about 100 μm to about 200 μm, most preferably from about 100 μm to about 150 μm. The pore size of the pores ranges from about 0.1 μm to about 10 μm, preferably from about 0.1 μm to about 2.0 μm. The porosity of the pores is about 50
% To about 90%, preferably about 60% to about 85%.
本発明の高分子微多孔性皮膜からなる電気泳動用支持
体は、特公昭55−31418、特開昭50−12256、特開昭55−
76360、特開昭63−262549、特開昭63−262550等に記載
の公知の方法に従って製造することができる。The support for electrophoresis comprising the polymer microporous film of the present invention is disclosed in JP-B-55-31418, JP-A-50-12256, and JP-A-55-
76360, JP-A-63-262549, JP-A-63-262550 and the like.
高分子微多孔性皮膜を構成する高分子材料として、ニ
トロセルロース、セルロースアセテート(セルロースジ
アセテート、セルローストリアセテート等)、セルロー
スアセテートブチレート、セルロースプロピオネートの
如きセルロースエステル、ポリアミド樹脂、ポリ塩化ビ
ニル樹脂等がある。高分子材料は1種単独で、又は2種
以上混合して用いることができる。これらの高分子材料
の中でもセルロースエステルおよびポリアミド樹脂が好
ましく、セルロースアセテート(セルロースジアセテー
ト、セルローストリアセテート)は最も好ましい。Nitrocellulose, cellulose acetate (cellulose diacetate, cellulose triacetate, etc.), cellulose ester such as cellulose acetate butyrate, cellulose propionate, polyamide resin, polyvinyl chloride resin Etc. The polymer materials can be used alone or in combination of two or more. Among these polymer materials, cellulose esters and polyamide resins are preferred, and cellulose acetate (cellulose diacetate, cellulose triacetate) is most preferred.
添加剤として用いられるカルボキシル基の炭素原子を
含めて炭素原子数10から27の範囲の高級脂肪酸は一般式 CnH2n+1COOH(nは8から26までの整数) で表わされる直鎖状又は分岐状の飽和カルボン酸であ
る。前記一般式で表わされる高級脂肪酸はいずれか1種
を用いてもよいし、任意の2種又は3種以上を併用して
もよい。高級脂肪酸の含有量は高分子微多孔性皮膜を構
成する高分子材料に対して、重量比で、約10ppmから約3
000ppmの範囲(溶解度が3000ppm以下の脂肪酸の場合に
は約10ppmから溶解度の範囲内)、好ましくは約10ppmか
ら約1000ppmの範囲(溶解度が1000ppm以下の脂肪酸の場
合には約10ppmから溶解度の範囲内)である。Higher fatty acid in the range of carbon atoms 10 27 including the carbon atom of the carboxyl group used as an additive formula C n H 2n + 1 COOH ( n is an integer from 8 to 26) linear represented by Or a branched saturated carboxylic acid. Any of the higher fatty acids represented by the above general formula may be used alone, or two or more arbitrary fatty acids may be used in combination. The content of the higher fatty acid is from about 10 ppm to about 3% by weight relative to the polymer material constituting the polymer microporous film.
000 ppm range (about 10 ppm to solubility for fatty acids with 3000 ppm or less solubility), preferably about 10 ppm to about 1000 ppm (about 10 ppm to solubility for fatty acids with 1000 ppm or less solubility) ).
高級脂肪酸の具体例とその好ましい添加量は次のとお
りである。Specific examples of the higher fatty acids and their preferable addition amounts are as follows.
(「C数字」はカルボキシル基の炭素原子を含めた炭素
原子数、注記のないものは直鎖状脂肪酸) これらの高級脂肪酸のうちで好ましいものはノナデカ
ン酸(ノナデシル酸)、エイコサン酸(アラキジン
酸)、ヘンエイコサン酸、ドコサン酸(ベヘン酸)、ト
リコサン酸、テトラコサン酸(リグノセリン酸)、ペン
タコサン酸、ヘキサコサン酸(セロチン酸)である。("C number" is the number of carbon atoms including the carbon atom of the carboxyl group, those without notes are linear fatty acids) Preferred among these higher fatty acids are nonadecanoic acid (nonadecylic acid), eicosanoic acid (arachidic acid), heneicosanoic acid, docosanoic acid (behenic acid), tricosanoic acid, tetracosanoic acid (lignoceric acid), pentacosanoic acid, and hexacosanoic acid ( (Cerotic acid).
高分子微多孔性皮膜には、公知の可塑剤又は湿潤剤を
含有させることができる。可塑剤又は湿潤剤の含有量は
微多孔性皮膜に柔軟性をもたせるために、高分子材料に
対して、重量比で、約1%〜約20%の範囲である。有用
な可塑剤又は湿潤剤の具体例として、エチレングリコー
ル、ジエチレングリコール、プロピレングリコール、テ
トラメチレングリコール、グリセロールモノアセチルエ
ステルのようなジオール類、グリセロール、枸櫞酸トリ
エチル、枸櫞酸トリブチル、枸櫞酸トリメチル、蓚酸ジ
エチル、蓚酸ジプロピル、トリブチリン(グリセロール
トリブチレート)、トリアセチン(グリセロールトリア
セテート)、琥珀酸ジエチル、琥珀酸ジブチル等があ
る。The polymer microporous film may contain a known plasticizer or wetting agent. The content of the plasticizer or wetting agent is in the range of about 1% to about 20% by weight with respect to the polymer material in order to make the microporous film flexible. Specific examples of useful plasticizers or wetting agents include diols such as ethylene glycol, diethylene glycol, propylene glycol, tetramethylene glycol, glycerol monoacetyl ester, glycerol, triethyl citrate, tributyl citrate, trimethyl citrate. , Diethyl oxalate, dipropyl oxalate, tributyrin (glycerol tributyrate), triacetin (glycerol triacetate), diethyl succinate, dibutyl succinate and the like.
微多孔高分子皮膜の製造方法について説明する。まず
高分子材料を溶剤と高級脂肪酸、さらに所望により添加
される可塑剤又は湿潤剤成分を後述する混合溶剤に実質
的に一様に溶解する。得られた溶液は前記諸特許明細書
等に記載の公知の方法に従って微多孔性皮膜を調製す
る。例えば、一様な溶液を平滑表面の仮支持体の上に流
延塗布し、コントロールされた温度のもとで乾燥させ、
形成された皮膜を仮支持体から剥離することにより微多
孔高分子皮膜が得られる。A method for producing the microporous polymer film will be described. First, a polymer material is substantially uniformly dissolved in a solvent, a higher fatty acid, and a plasticizer or a wetting agent component to be added if necessary, in a mixed solvent described later. The resulting solution is used to prepare a microporous film according to a known method described in the above-mentioned patent specifications and the like. For example, a uniform solution is cast on a temporary support having a smooth surface, dried under a controlled temperature,
By peeling the formed film from the temporary support, a microporous polymer film is obtained.
混合溶剤とは、親溶剤、貧溶剤および非溶剤の3者を
混合した混合溶剤をいう。ここで親溶剤とは高分子材料
を溶解するものをいい、貧溶剤とは親溶剤とは相溶性が
あるが、実質的に高分子材料を溶解させず、膨潤させる
のみで、しかも親溶剤よりも沸点の高いものをいい、非
溶剤とは親溶剤又は貧溶剤と相溶性があるが、高分子材
料を溶解も膨潤もしないもので、かつ親溶剤より沸点の
高いものをいう。The mixed solvent refers to a mixed solvent obtained by mixing the three components of a lipophilic solvent, a poor solvent and a non-solvent. Here, the lipophilic solvent means a substance that dissolves the polymer material, and the poor solvent is compatible with the lipophilic solvent, but does not substantially dissolve the polymer material, only swells, and more than the lipophilic solvent. A non-solvent is one that is compatible with a lyophilic solvent or a poor solvent, but does not dissolve or swell the polymer material and has a higher boiling point than the lipophilic solvent.
親溶剤の具体例をあげると、例えば、セルロースアセ
テートに対して塩化メチレン、アセトン、蟻酸メチル
等、ニトロセルロースに対してジエチルエーテル、酢酸
メチル、アセトン、酢酸等、ポリアミド樹脂に対してメ
タノール、エタノール等がある。Specific examples of the lyophilic solvent include, for example, methylene chloride, acetone, methyl formate and the like for cellulose acetate, diethyl ether, methyl acetate, acetone, acetic acid and the like for nitrocellulose, and methanol and ethanol for the polyamide resin. There is.
貧溶剤の具体例をあげると、例えば、セルロースアセ
テートに対してテトラヒドロフラン、メタノール等、ニ
トロセルロースに対してブタノール、エタノール等、ボ
リアミド樹脂に対してテトラヒドロフラン、ジオキサ
ン、酢酸エチル等がある。Specific examples of the poor solvent include, for example, tetrahydrofuran and methanol for cellulose acetate, butanol and ethanol for nitrocellulose, and tetrahydrofuran, dioxane and ethyl acetate for polyamide resin.
非溶剤としては多くの場合水が用いられる。 Water is often used as the non-solvent.
これらの溶剤の親溶剤、貧溶剤、非溶剤の区別は必ず
しも一義的なものではない。上述した製造法は本発明の
電気泳動用支持体を得るための1例である。The distinction between the lipophilic, poor and non-solvent of these solvents is not always unique. The above-described production method is an example for obtaining the support for electrophoresis of the present invention.
溶媒の使用法、特に親溶剤、貧溶剤の使用法に関して
は特公昭55−31418、特開昭50−122565、特開昭51−763
60等の明細書に記載の手法を応用することができる。With respect to the use of the solvent, especially the use of the lipophilic solvent and the poor solvent, JP-B-55-31418, JP-A-50-122565, JP-A-51-763.
The method described in the specification such as 60 can be applied.
本発明の電気泳動用支持体に用いられる微多孔性高分
子皮膜の孔径分布範囲は、E.W.Wash Bahn著「Proc.Nat
l.Acad.Sci.」No 1,1115(1921)、慶伊富長著 共立全
書157「吸着」(130頁)、近藤連一著「多孔材料」(技
報堂、1973年)、「化学工学」31巻60〜66頁(1967年)
等に記載の水銀厚入法で測定された値である。孔径分布
範囲は約0.1μmから約10μmの範囲、好ましくは約0.1
μmから約2.0μmの範囲に97%の径が収まるものを用
いることができる。ここで孔径分布とは水銀圧入法によ
り得られた孔径−累積率表により,累積率が3%から97
%の範囲に相当する孔径範囲を意味する。The pore size distribution range of the microporous polymer film used for the electrophoresis support of the present invention is described in Proc. Nat by EWWash Bahn.
l.Acad.Sci. ”No 1,1115 (1921), Tominaga Keii, Kyoritsu Zensho 157,“ Adsorption ”(p.130), Renichi Kondo,“ Porous Materials ”(Gihodo, 1973),“ Chemical Engineering ” Volume 31, 60-66 (1967)
Etc. are values measured by the mercury penetration method. The pore size distribution ranges from about 0.1 μm to about 10 μm, preferably about 0.1 μm.
Those having a diameter of 97% within the range from μm to about 2.0 μm can be used. Here, the pore size distribution refers to a pore size-cumulative ratio table obtained by the mercury intrusion method, and shows that the cumulative ratio ranges from 3% to 97%.
% Means a range of pore diameters corresponding to the range of%.
実施例1〜19及び比較例1 [微多孔性皮膜の調製] 下記の組成の実質的に一様な溶液を調製し、各溶液を
表面が平滑表面のガラス板(仮支持体)の上に厚さ1mm
に流延し、25℃で乾燥し、皮膜の全面がほぼ一様に白く
なった時にガラス板から剥ぎとり、枠にはってさらに10
0℃で1時間乾燥して微多孔性皮膜を調製した、得られ
た微多孔性皮膜はいずれも乾燥厚さ約150μm、孔径範
囲0.1μm〜2.0μmの範囲にあった。Examples 1 to 19 and Comparative Example 1 [Preparation of microporous film] A substantially uniform solution having the following composition was prepared, and each solution was placed on a glass plate (temporary support) having a smooth surface. 1mm thick
And dried at 25 ° C. When the entire surface of the film becomes almost uniformly white, peel it off from the glass plate and put it on a frame for another 10 minutes.
The resulting microporous film was dried at 0 ° C. for 1 hour to prepare a microporous film. Each of the obtained microporous films had a dry thickness of about 150 μm and a pore size range of 0.1 μm to 2.0 μm.
溶液の組成 セルローストリアセテート (アセチル基含有量43.5%) 30g セルロースジアセテート (アセチル基含有量39.4%) 30g グリセロール 4.2g トリブチリン 4.8g トリフェニルホスフェート 1.2g メチレンクロリド 600g メタノール 280g 水 40g ヒドロキシプロピルセルロース (ヒドロキシプロピル基含有量64.0%) 300mg 高級脂肪酸:下記の化合物 セルローストリアセテートとセルロースジアセテート
の合計量に対し、それぞれ重量比で 10ppm;100ppm;1000ppm (「c数字」はカルボキシル基の炭素原子を含めた炭素
原子数を表わす) [性能評価実験1] 実施例1〜19及び比較例1で調製した微多孔性皮膜60
種を70mm×200mmのサイズに裁断し、それぞれにpH8.6の
0.07MベロナールpH緩衝水溶液(2.30gのベロナールと1
1.80gのベロナールナトリウムを蒸留水に溶解し、全量
を25℃で1000mLにしたもの)を含浸させ、これらの皮膜
を同じ緩衝液を充填した電気泳動槽にセットし、濾紙を
ブリッジとして載置した。マイクロピペットで、線状に
10mmにわたり全量0.1μLになるようにして、ヒト血清
を微多孔性皮膜の陰極端から15mmの距離に塗布した。皮
膜面に沿って血清の塗布線と垂直な方向(70mmの幅方
向)に0.6mA/cmの直流定電流を40分印加して血清蛋白を
電気泳動し、泳動後皮膜をポンソー−3R染色液(ポンソ
ー−3R 3g、トリクロロ酢酸6g、水91gの組成比の染色水
溶液)に60秒浸漬して染色し、1%酢酸水溶液で2分間
づつ4回洗浄した。Solution composition Cellulose triacetate (acetyl group content 43.5%) 30 g Cellulose diacetate (acetyl group content 39.4%) 30 g glycerol 4.2 g tributyrin 4.8 g triphenyl phosphate 1.2 g methylene chloride 600 g methanol 280 g water 40 g hydroxypropyl cellulose (hydroxypropyl Higher fatty acid: The following compounds: 10 ppm; 100 ppm; 1000 ppm by weight based on the total amount of cellulose triacetate and cellulose diacetate (“c number” indicates carbon atoms including carboxyl group carbon atoms) Represents a number) [Performance Evaluation Experiment 1] Microporous film 60 prepared in Examples 1 to 19 and Comparative Example 1
Seeds are cut to a size of 70 mm x 200 mm, each having a pH of 8.6
0.07M veronal pH buffer aqueous solution (2.30 g of veronal and 1
Dissolve 1.80 g of veronal sodium in distilled water, make the total volume 1000 mL at 25 ° C), set these films in an electrophoresis tank filled with the same buffer, and place the filter paper as a bridge. did. With a micropipette, linearly
Human serum was applied at a distance of 15 mm from the cathode end of the microporous film in a total volume of 0.1 μL over 10 mm. A constant DC current of 0.6 mA / cm is applied for 40 minutes in the direction perpendicular to the serum coating line (70 mm width direction) along the surface of the film to electrophoretize the serum proteins. After the electrophoresis, the film is stained with Ponceau-3R staining solution. (A dyeing aqueous solution having a composition ratio of 3 g of Ponceau-3R, 6 g of trichloroacetic acid, and 91 g of water) was dyed by immersion for 60 seconds, and washed with a 1% aqueous acetic acid solution four times for 2 minutes each.
洗浄後皮膜の両面に濾紙をあてて、洗浄液を吸い取っ
てから、皮膜を風乾した。After washing, filter paper was applied to both sides of the film, the cleaning solution was sucked out, and the film was air-dried.
風乾後、血清蛋白の泳動パターンを観察したところ、
すべての微多孔性高分子皮膜において蛋白分画の数は5
で、βリポ蛋白による6番目の分画は出現していなかっ
た。染色された泳動パターンの光学濃度変化をデンシト
メーターによりを測定したところ、泳動パターンは第1
図に示す5つのピーク(それぞれALB、α1、α2、
β、γという)に明確にわかれた。After air drying, the serum protein migration pattern was observed.
The number of protein fractions in all microporous polymer membranes was 5
Thus, the sixth fraction by β-lipoprotein did not appear. When the change in optical density of the stained electrophoresis pattern was measured by a densitometer,
The five peaks shown in the figure (ALB, α 1 , α 2 ,
β and γ).
第1図に示す泳動パターンの光学濃度変化曲線につい
て、分解能を次ぎのように定義する。The resolution of the optical density change curve of the migration pattern shown in FIG. 1 is defined as follows.
ピークα2、βと極小値C点について X1=α2の光学濃度値−C点の光学濃度値 X2=βの光学濃度値−C点の光学濃度値 とし、X1、X2が大きい方が分離性がよいとする。Regarding the peaks α 2 and β and the minimum value C point, X 1 = optical density value of α 2 −optical density value of point C X 2 = optical density value of β−optical density value of point C, where X 1 and X 2 are It is assumed that the larger is the better the separability.
実施例1〜19及び比較例1で作成した微孔性多孔膜に
ついてのX1、X2の値は下記のとおりである。下記のデー
タから、本発明の微孔性多孔膜はX1、X2の値が大きく分
離性が良いことが明らかである。なお下記のデータは泳
動パターンの光学濃度変化曲線グラフ上の距離(単位m
m)であって、光学濃度値の差ではない。−は高級脂肪
酸が溶解しないことを表わす。The values of X 1 and X 2 for the microporous porous membranes prepared in Examples 1 to 19 and Comparative Example 1 are as follows. From the following data, it is clear that the microporous membrane of the present invention has large values of X 1 and X 2 and has good separability. The following data is the distance on the optical density change curve graph of the migration pattern (unit: m
m), not the difference in optical density values. -Indicates that the higher fatty acid is not dissolved.
[性能評価実験2] 性能評価実験1において、電気泳動後、ポンソー−3R
で染色した後、泳動パターンを測定した皮膜を、オゾン
化シッフ法によるβリポ蛋白の青色染色法で染色した
後、βリポ蛋白のピーク位置(βL)とβピーク位置
(β)との距離(βL−β)を測定した。なお下記のデ
ータは泳動パターンの光学濃度変化曲線グラフ上の距離
(単位mm)を表わす。−は高級脂肪酸が溶解しないこと
を表わす。 [Performance evaluation experiment 2] In performance evaluation experiment 1, after electrophoresis, Ponceau-3R
After staining the membrane with the electrophoresis pattern, the membrane was stained by the ozone-Schiff blue staining method for β lipoprotein, and then the distance between the β lipoprotein peak position (β L ) and the β peak position (β) the (β L -β) was measured. The following data represents the distance (unit: mm) on the optical density change curve graph of the migration pattern. -Indicates that the higher fatty acid is not dissolved.
性能評価実験1において、X1、X2が大きかった皮膜は
βリポ蛋白のピーク位置とβピーク位置との距離が大き
いので、βリポ蛋白による泳動パターンの干渉が排除さ
れて、α2ピーク位置とβピーク位置とが鮮明に識別で
きた。In the performance evaluation experiment 1, in the film having large X 1 and X 2 , the distance between the β lipoprotein peak position and the β peak position was large, so that interference of the migration pattern due to β lipoprotein was eliminated, and the α 2 peak position was eliminated. And the β peak position could be clearly distinguished.
オゾン化シッフ法によるβリポ蛋白の青色染色法 シッフ染色液の調製法 ヒロ亜硫酸ナトリウム13.7g、濃塩酸21mL、フクシン
8.0gを蒸留水に溶解して全量を2000mLとし、一晩スター
ラーで撹拌した。ついでこの液に活性炭を大サジ5杯加
え、15分かけて濾紙で不溶解成分を濾過し、濾取した液
を約4℃で冷蔵保存した。Blue staining of β-lipoprotein by the ozonated Schiff method Preparation of Schiff staining solution 13.7 g of sodium sodium sulfite, 21 mL of concentrated hydrochloric acid, fuchsin
8.0 g was dissolved in distilled water to make a total volume of 2000 mL, and stirred overnight with a stirrer. Next, 5 tablespoons of activated carbon were added to this solution, and the insoluble components were filtered with filter paper over 15 minutes, and the filtered solution was refrigerated at about 4 ° C.
シッフ洗浄液の調製法 ピロ亜硫酸ナトリウム4.3g、濃塩酸9mLを蒸留水887g
に溶解し、95%エタノール100mLを加えた。Preparation method of Schiff washing solution 4.3 g of sodium pyrosulfite and 9 mL of concentrated hydrochloric acid in 887 g of distilled water
And 100 mL of 95% ethanol was added.
染色操作 性能評価実験1において、ポンソー−3Rで染色し泳動
ターンを測定した皮膜を、オゾン発生器(日本オゾン
社、東京)により、20分間オゾン酸化した。Dyeing operation In the performance evaluation experiment 1, the film dyed with Ponceau-3R and measured for the electrophoretic turn was ozone-oxidized for 20 minutes by an ozone generator (Ozone Japan, Tokyo).
オゾン酸化した皮膜をシッフ洗浄液に数秒浸漬した
後、シッフ染色液で10分間染色し、次いでシッフ洗浄液
で10分間づつ3回洗浄を繰り返し、皮膜を濾紙ではさん
で乾燥させた。After the ozone-oxidized film was immersed in a Schiff cleaning solution for several seconds, the film was dyed with a Schiff dyeing solution for 10 minutes, and then washed three times with a Schiff cleaning solution for 10 minutes each, and the film was dried with filter paper.
第1図は実施例1〜19(本発明)及び比較例1(従来技
術)による微多孔性皮膜を用いてヒト血清を電気泳動し
染色して得られた泳動パターンの光学濃度変化をデンシ
トメーターによりを測定した光学濃度変化曲線の模式図
である。曲線は血清蛋白成分ALB、α1、α2、β、γ
のピークとそれらの間隔を表わす。FIG. 1 shows the change in optical density of the migration pattern obtained by electrophoresing and staining human serum using the microporous film according to Examples 1 to 19 (invention) and Comparative Example 1 (prior art). It is a schematic diagram of the optical density change curve measured by the meter. The curve shows serum protein components ALB, α 1 , α 2 , β, γ
And their intervals.
───────────────────────────────────────────────────── フロントページの続き (56)参考文献 特開 昭63−262550(JP,A) 特開 昭63−262549(JP,A) 特開 昭50−122565(JP,A) 特公 昭55−31418(JP,B2) (58)調査した分野(Int.Cl.6,DB名) G01N 27/447──────────────────────────────────────────────────続 き Continuation of the front page (56) References JP-A-63-262550 (JP, A) JP-A-63-262549 (JP, A) JP-A-50-122565 (JP, A) 31418 (JP, B2) (58) Field surveyed (Int. Cl. 6 , DB name) G01N 27/447
Claims (2)
高級脂肪酸の少なくとも1種を高分子に対して重量比で
10ppmから3000ppmの範囲又は10ppmから溶解度の範囲内
で含有することを特徴とする高分子微多孔性皮膜からな
る電気泳動用支持体。1. An additive comprising at least one higher fatty acid having 10 to 27 carbon atoms in a weight ratio to a polymer.
An electrophoresis support comprising a polymer microporous film, wherein the support is contained in the range of 10 ppm to 3000 ppm or in the range of 10 ppm to solubility.
ルロースエステル、ポリアミド、ポリ塩化ビニルからな
る群から選択された少なくとも1種の高分子である請求
項1に記載の電気泳動用支持体。2. The support for electrophoresis according to claim 1, wherein the polymer constituting the polymer microporous film is at least one polymer selected from the group consisting of cellulose ester, polyamide, and polyvinyl chloride. body.
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP1126287A JP2764306B2 (en) | 1989-05-19 | 1989-05-19 | Electrophoresis support |
| US07/525,963 US5068019A (en) | 1989-05-19 | 1990-05-18 | Electrophoresis film support |
| EP90109660A EP0398388B1 (en) | 1989-05-19 | 1990-05-21 | Electrophoresis film support |
| DE69029599T DE69029599T2 (en) | 1989-05-19 | 1990-05-21 | Carrier film for electrophoresis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP1126287A JP2764306B2 (en) | 1989-05-19 | 1989-05-19 | Electrophoresis support |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH02306160A JPH02306160A (en) | 1990-12-19 |
| JP2764306B2 true JP2764306B2 (en) | 1998-06-11 |
Family
ID=14931479
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP1126287A Expired - Fee Related JP2764306B2 (en) | 1989-05-19 | 1989-05-19 | Electrophoresis support |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2764306B2 (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5531418B2 (en) | 2009-02-23 | 2014-06-25 | 富士ゼロックス株式会社 | Image forming apparatus |
-
1989
- 1989-05-19 JP JP1126287A patent/JP2764306B2/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5531418B2 (en) | 2009-02-23 | 2014-06-25 | 富士ゼロックス株式会社 | Image forming apparatus |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH02306160A (en) | 1990-12-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Dobashi et al. | Enantioselective hydrophobic entanglement of enantiomeric solutes with chiral functionalized micelles by electrokinetic chromatography | |
| Noble | Electrophoretic separation of plasma lipoproteins in agarose gel | |
| Doss | Analytical and preparative thin-layer chromatography of porphyrin methyl esters | |
| US5453171A (en) | Heparin-selective polymeric membrane electrode | |
| US5068019A (en) | Electrophoresis film support | |
| Lelièvre et al. | Chiral separations of underivatized arylpropionic acids by capillary zone electrophoresis with various cyclodextrins Acidity and inclusion constant determinations | |
| PONDER | The cell membrane and its properties | |
| US4006069A (en) | Support for electrophoretic analysis | |
| Nishi et al. | Chiral separation of drugs using cyclodextrins in capillary zone electrophoresis | |
| Mead et al. | The investigation of “mid-band” lipoproteins using polyacrylamide gel electrophoresis | |
| US4128470A (en) | Supports for electrophoresis and process for the production of the same | |
| EP0167373A2 (en) | Element for electrophoresis | |
| Dunn et al. | [8] Two-dimensional polyacrylamide gel electrophoresis | |
| JP2764306B2 (en) | Electrophoresis support | |
| JP2802645B2 (en) | Electrophoresis support | |
| Beckering JR et al. | A rapid method for lipoprotein electrophoresis using cellulose acetate as support medium | |
| JPS63262550A (en) | Support for electrophoresis | |
| Fless et al. | Physicochemical characterization of rhesus low density lipoproteins | |
| Bodman | Agar gel, starch block, starch gel, and sponge rubber electrophoresis | |
| JPH0476450A (en) | Supporting body for electrophoresis | |
| JP3196123B2 (en) | Cellulose acetate support for electrophoresis | |
| JP3088861B2 (en) | Dye aqueous solution for protein staining, staining kit and staining method | |
| US4696958A (en) | Electrophoretic technique for separation of lipoproteins and electrophoretic gel for use therein | |
| Frey et al. | Rapid staining of proteins in ultrathin‐layer isoelectric focusing in polyacrylamide gels | |
| JPH02150760A (en) | Dyeing treatment in electrophoresis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080403 Year of fee payment: 10 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090403 Year of fee payment: 11 |
|
| LAPS | Cancellation because of no payment of annual fees |